Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $17.64 USD
Change Today -1.27 / -6.72%
Volume 113.5K
As of 4:00 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

atyr pharma inc (LIFE) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/4/15 - $28.29
52 Week Low
05/7/15 - $12.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ATYR PHARMA INC (LIFE)

Related News

No related news articles were found.

atyr pharma inc (LIFE) Related Businessweek News

No Related Businessweek News Found

atyr pharma inc (LIFE) Details

aTyr Pharma, Inc. engages in the discovery and clinical development of protein based therapeutics for patients suffering from severe and rare diseases. The company is developing Resolaris, which is in Phase Ib/II clinical trials in adult patients with facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component. Its products pipeline also includes Resolaris for treatment of patients with early onset facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component and limb-girdle muscular dystrophies, as well as rare pulmonary diseases with an immune component. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory domain program. The company was founded in 2005 and is headquartered in San Diego, California.

53 Employees
Last Reported Date: 06/18/15
Founded in 2005

atyr pharma inc (LIFE) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $410.0K
Chief Medical Officer
Total Annual Compensation: $265.2K
Compensation as of Fiscal Year 2014.

atyr pharma inc (LIFE) Key Developments

aTyr Pharma Inc. Announces Executive Changes

aTyr Pharma Inc. announced that it will transition oversight of clinical development and operations to Ms. Kelly Blackburn and Melissa Ashlock, M.D. as David Weiner, M.D., transitions from his current position as aTyr's Chief Medical Officer into a clinical advisory role through the end of the first quarter of 2016.

aTyr Pharma, Inc. Announces Resignation of President and Chief Operating Officer Frederic Chereau

aTyr Pharma Inc. announced the resignation of President and Chief Operating Officer Frederic Chereau to pursue other opportunities, effective immediately.

aTyr Pharma Inc.(NasdaqGS:LIFE) added to Russell 2000 Index

aTyr Pharma Inc. will be added to Russell 2000 Index


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LIFE:US $17.64 USD -1.27

LIFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LIFE.
View Industry Companies

Industry Analysis


Industry Average

Valuation LIFE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATYR PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at